Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome: A Retrospective Study of Seventy Patients With Vascular Involvement by Emmi, Giacomo et al.
Adalimumab-Based Treatment Versus
Disease-Modifying Antirheumatic Drugs for
Venous Thrombosis in Behcet’s Syndrome
A Retrospective Study of Seventy Patients With Vascular Involvement
Giacomo Emmi,1 Antonio Vitale,2 Elena Silvestri,1 Maria Boddi,1 Matteo Becatti,3
Claudia Fiorillo,3 Claudia Fabiani,4 Bruno Frediani,2 Lorenzo Emmi,3 Gerardo Di Scala,1
Matteo Goldoni,5 Alessandra Bettiol,3 Augusto Vaglio,6 Luca Cantarini,2 and Domenico Prisco1
Objective. Since Behcet’s syndrome (BS) is the pro-
totype of inflammation-induced thrombosis, immunosup-
pressants are recommended in place of anticoagulants.
We undertook this study to assess the clinical efficacy and
the corticosteroid-sparing effect of adalimumab (ADA)–
based treatment versus disease-modifying antirheumatic
drug (DMARD) therapy in a large retrospective cohort of
patients with BS-related venous thrombosis.
Methods. We retrospectively collected data on 70
BS patients treated with DMARDs or ADA-based regi-
mens (ADA with or without DMARDs) because of venous
complications. Clinical and imaging evaluations were
performed to define vascular response. We explored dif-
ferences in outcomes between ADA-based regimens and
DMARDs with respect to efficacy, corticosteroid-sparing
role, and time on treatment. We also evaluated the role of
anticoagulants as concomitant treatment.
Results. After a mean  SD follow-up period of
25.7  23.2 months, ADA-based regimens induced clini-
cal and imaging improvement of venous thrombosis more
frequently (P = 0.001) and rapidly (P < 0.0001) than did
DMARDs. The mean dose of corticosteroids adminis-
tered at the last follow-up visit was significantly lower
with ADA-based regimens than with DMARDs (P <
0.0001). The time on treatment was significantly longer
with ADA plus DMARDs than with DMARDs alone (P =
0.002). No differences were found in terms of efficacy and
time on treatment between DMARDs or ADA-based regi-
mens among patients who received anticoagulants and
those who did not.
Conclusion. In this large retrospective study, we
have shown that ADA-based regimens are more effective
and rapid than DMARDs in inducing resolution of venous
thrombosis in BS patients, allowing reduction of steroid
exposure. Moreover, our findings suggest that anticoagu-
lation does not modify the efficacy of either ADA-based
regimens or DMARDs for venous complications.
Behcet’s syndrome (BS) is a systemic vasculitis
characterized by protean manifestations such as mucocu-
taneous and ocular lesions as well as articular, neurologic,
gastrointestinal, and vascular involvement (1). Vascular
manifestations occur in up to 50% of patients and affect
both venous and arterial vessels of variable size; deep vein
thrombosis (DVT) and recurrent superficial vein throm-
bophlebitis (SVT) of lower extremities are the most com-
mon vascular manifestations of the disease. Venous
thrombosis occurs more frequently during active disease
in male subjects and tends to recur, making it one of the
most important causes of morbidity and mortality in BS
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patients (2). Systemic inflammation seems to be the main
trigger of thrombosis. Although the pathogenic mecha-
nisms of BS-related thrombosis are still incompletely
understood, we have recently demonstrated that neu-
trophils are able to induce deep modifications in fibrino-
gen structure, which becomes more resistant to plasmin
(3). These data support the European League Against
Rheumatism (EULAR) recommendations for the man-
agement of thrombosis in BS patients, which suggest the
use of immunosuppressants as disease-modifying anti-
rheumatic drugs (DMARDs) rather than oral anticoagu-
lation as first-line therapy (4,5).
Recently, several studies have shown the efficacy
of anti–tumor necrosis factor (anti-TNF) agents for BS-
related vascular complications (6–9), especially for patients
with arterial involvement (10). However, there are no
prospective controlled trials or large retrospective studies
focusing on the treatment of deep and/or superficial vein
thrombosis in BS patients. In the present study, we evalu-
ated the clinical efficacy and the corticosteroid-sparing
effect of adalimumab (ADA)–based regimens versus
DMARDs alone in a large retrospective cohort of patients
with BS-related venous thrombosis.
PATIENTS AND METHODS
We retrospectively collected clinical data on patients
diagnosed as having BS and treated with DMARDs as the sole
immunosuppressive therapy or with ADA-based regimens (ADA
alone or combined with DMARDs) because of recurrent venous
vascular manifestations. All patients were seen at the Behcet
Figure 1. Study flow diagram. BS = Behcet’s syndrome; DVT = deep vein thrombosis; SVT = superficial vein thrombophlebitis; anti-TNF = anti–
tumor necrosis factor; ADA = adalimumab; DMARDs = disease-modifying antirheumatic drugs.
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Centre of the University Hospital of Florence between January
2009 and January 2017. The diagnosis of BS was based on the
International Criteria for Behcet’s disease (11). Venous involve-
ment included DVTand SVTof the lower and upper limbs; SVT
and DVT were defined as recurrent if they occurred at least
twice during patient observation. Patients with BS-related arte-
rial involvement and/or venous disease affecting sites other than
lower and upper limbs were excluded from the study (Figure 1).
In accordance with our clinical practice, patients with
venous events were clinically and sonographically evaluated
every 4 weeks for the first 3 months after the event, and then
every 3 months or in case of BS relapse; all ultrasounds were
performed by the same trained vascular ultrasound specialist
(MB). DVT and SVT were diagnosed by the appearance of
bilateral compression of upper or lower limb on ultrasound.
Diagnostic criteria were cross-sectional vein incompressibility,
direct thrombus imaging with vein enlargement, and abnor-
mal spectral and color Doppler flow (12). The Doppler ultra-
sound response was defined as follows: 1) complete resolution
of venous thrombosis; 2) partial response with revascularization,
characterized by the presence of non–hemodynamically relevant
parietal thrombosis; 3) no response or thrombosis progression.
Clinical response was defined as the disappearance of signs and
symptoms related to DVT and/or SVT. A complete response
was defined as both a clinical and imaging resolution of throm-
bosis; a partial response was represented by a clinical resolution
plus a partial instrumental response or no progression of throm-
bosis; no response was defined as the absence of both clinical
and imaging response. Globally, both complete response and
partial response have been defined in the text as “vascular
response.” The occurrence of postthrombotic syndrome was not
considered in the evaluation of vascular outcome.
The data collected included age at BS onset, HLA–B51
positivity, clinical manifestations occurring at any time since dis-
ease onset, and all available information regarding treatment
(time at ADA-based regimen or DMARD initiation, concomi-
tant therapies, corticosteroid dosages at the start of treatment
and at last follow-up visit or at disease relapse). We also assessed
the clinical and imaging response to different treatments, the
time required to achieve clinical response, the occurrence of vas-
cular relapses during treatments, the time elapsed between the
start of DMARDs or ADA-based treatment and vascular
relapse, and any oral anticoagulant treatment associated with
ADA-based regimens or DMARDs. Specific aims of this study
were 1) to explore differences in the efficacy of treating SVTand
DVT between ADA-based regimens and DMARDs alone,
focusing on response rates and time to vascular response; 2) to
compare the corticosteroid-sparing role of ADA-based regimens
with that of DMARDs alone; 3) to compare the time on treat-
ment with ADA-based regimens and DMARDs alone; and 4) to
evaluate the role of concomitant anticoagulant therapy on vascu-
lar responses in patients treated with ADA-based regimens or
DMARDs alone.
GraphPad Prism 6.0 software was used for statistical
computation. Continuous variables are reported as the mean 
SD or the median (range) as appropriate, and categorical vari-
ables are reported as the number (%). For pairwise comparisons,
the Mann-Whitney U test was used for continuous variables after
having determined their non-Gaussian distribution using the
Anderson–Darling test; Fisher’s exact test was used for categori-
cal variables. We analyzed the time on treatment, defined as the
time elapsed between the start of the therapy (for venous
complications) and the discontinuation of treatment or last
follow-up visit, by using the Kaplan-Meier method. Statistical
differences in survival rates were assessed using the Mantel-Cox
log rank test. P values less than 0.05 were considered significant.
The study was approved by the Ethics Committee of
Careggi Hospital. All patients gave their informed consent for
collection and publication of data, and the study was conducted
in accordance with the Declaration of Helsinki.
RESULTS
Of the 275 patients with BS seen at our center dur-
ing the study period, 78 had had DVTand/or SVTof the
upper or lower limbs. Eight of the 78 patients were
excluded from this study because they had been treated
with anti-TNF agents other than ADA. The remaining 70
patients (37 men and 33 women) were included in the
Table 1. Demographic and clinical features of patients enrolled in
the study and clinical manifestations recorded at the start of ADA-
based regimens or DMARD therapy alone*
ADA-based
regimens
DMARDs
alone
Demographic and clinical
features
No. of men/women 18/17 19/16
Age, mean  SD years 42.8  11.2 53.8  32.1
Disease duration,
mean  SD months
106.6  107.5 123.4  113.9
Meeting ICBD 35 (100) 35 (100)
HLA–B51 positive 22 (62.9) 23 (65.7)
Oral aphthosis 35 (100) 35 (100)
Genital aphthosis 14 (40) 15 (42.9)
Ocular involvement 17 (48.6) 15 (42.9)
Skin manifestations 23 (65.7) 23 (65.7)
Arthritis/arthralgia 17 (48.6) 18 (51.4)
Intestinal involvement 11 (31.4) 14 (40)
Neurologic
manifestations
7 (20) 11 (31.4)
Vascular involvement 35 (100) 35 (100)
Other than vascular BS
manifestations at the start
of treatment
Oral aphthosis 22 (62.9) 20 (57.1)
Genital aphthosis 8 (22.9) 6 (17.1)
Ocular involvement 6 (17.1) 9 (25.7)
Skin manifestations 3 (8.6) 2 (5.7)
Arthritis/arthralgia 2 (5.7) 0 (0)
Intestinal involvement 1 (2.9) 2 (5.7)
Neurologic
manifestations
2 (5.7) 4 (11.4)
Specific vascular manifestations
Unilateral SVT 6 (17.1) 11 (31.4)
Bilateral SVT 9 (25.7) 4 (11.4)
Unilateral DVT 17 (48.6) 17 (48.6)
Bilateral DVT 11 (31.4) 7 (20)
* There were no significant differences between the groups, with the
exception of age (P = 0.009). Except where indicated otherwise, values
are the number (%). ADA = adalimumab; DMARD = disease-modifying
antirheumatic drug; ICBD = International Criteria for Behcet’s disease;
BS = Behcet’s syndrome; SVT = superficial vein thrombophlebitis;
DVT = deep vein thrombosis.
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study (Figure 1). Among the enrolled patients, 35 (18
men and 17 women) had been treated with ADA-based
regimens (ADA alone or combined with DMARDs) and
35 (19 men and 16 women) with DMARDs alone. Table 1
summarizes the demographic and clinical features of the
70 patients enrolled. Of the 35 patients who received
DMARDs alone, 18 (51%) were treated with azathio-
prine, 9 (26%) with cyclosporine, 5 (14%) with cyclophos-
phamide, and 3 (9%) with methotrexate. Of the 35
patients treated with ADA, 27 received ADA monother-
apy and 8 received ADA plus DMARDs (azathioprine in
7 patients and methotrexate in 1 patient). Apart from sev-
ere oral aphthosis, 10 of 35 patients treated with
DMARDs alone and 16 of 35 treated with ADA-based
regimens had vascular involvement as the sole disease
manifestation at the start of therapy.
During a mean  SD follow-up period of 25.7
 23.2 months, ADA-based regimens and DMARDs
were able to induce vascular responses in 34 of 35
patients (97.1%) and in 23 of 35 patients (65.7%),
respectively. The frequency of complete or partial vas-
cular responses was significantly higher among patients
treated with ADA-based regimens (P = 0.001).
Among those who initially presented with SVT,
vascular responses were observed in 3 of 4 patients
(75%) treated with ADA-based regimens and in 3 of 7
patients (42.86%) treated with DMARDs alone (P =
0.545). ADA-based regimens were used in patients with
SVT who had other disease manifestations (2 with ocu-
lar involvement, 1 with severe oral aphthosis and ery-
thema nodosum, and 1 with oral aphthosis and
arthritis). Among patients with initial DVT (17 treated
with ADA-based regimens and 12 with DMARDs),
ADA-based regimens induced a significantly higher vas-
cular response rate than did DMARDs (76.47% versus
33.33%; P = 0.029).
Figure 2. A and B, Overall time on treatment, assessed using the Kaplan-Meier method, in patients treated with adalimumab (ADA)–based regi-
mens (alone or in combination with disease-modifying antirheumatic drugs [DMARDs]) and patients treated with DMARDs alone (A) and in
patients treated with ADA monotherapy, patients treated with ADA plus DMARDs, and patients treated with DMARDs alone (B). In B,
* = log rank P value for the comparison of ADA plus DMARDs with DMARDs alone; # = log rank P value for the comparison of ADA
monotherapy with DMARDs alone. C, Survival rates with ADA-based regimens, in patients with Behcet’s syndrome (BS)–related vascular involve-
ment as the sole clinical manifestation at the start of treatment (baseline) and patients with additional BS manifestations at the start of treatment.
D, Survival rates with DMARD treatment, in patients with BS-related vascular involvement as the sole clinical manifestation at the start of treat-
ment (baseline) and patients with additional BS manifestations at the start of treatment.
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The mean  SD time required to achieve a vascu-
lar response (either complete or partial) was 3.7  1.7
weeks for ADA-based regimens and 6.3  1.2 weeks for
DMARDs. The time to response was significantly shorter
for those receiving ADA-based regimens than for those
receiving DMARDs alone (P < 0.0001 by log rank test).
The mean  SD dose of prednisone (or equiva-
lent) administered at the start of therapy was 23.1 
13.1 mg/day among patients treated with ADA-based
regimens and 26.2  20.2 mg/day among patients treat-
ed with DMARDs alone (P = 0.96). The mean  SD
dose of prednisone (or equivalent) administered at the
last follow-up visit was 3.6  3.4 mg/day in those
receiving ADA-based regimens and 8.3  3.7 mg/day in
those receiving DMARDs alone (P < 0.0001). The
mean  SD decrease in prednisone dose was 20.4 
13.1 mg/day in patients treated with ADA-based regi-
mens and 17.7  20.3 mg/day in patients treated with
DMARDs alone (P = 0.20).
The mean  SD prednisone dose administered at
the last follow-up visit for isolated vascular involvement
was 4.3  3.8 mg/day in patients treated with ADA-based
regimens and 10.2  4.6 mg/day in patients treated with
DMARDs alone (P = 0.002). The mean  SD prednisone
reductions for isolated vascular involvement were 20.0 
15.4 mg/day and 19.1  17.2 mg/day in the ADA and
DMARD groups, respectively (P = 0.908).
When we evaluated the time on treatment, we
observed that it was significantly longer in all patients
treated with ADA (both as monotherapy and combined
with DMARDs) than in those treated with DMARDs
alone (P = 0.001 by log rank test) (Figure 2A). Addition-
ally, the time on treatment was significantly longer in
patients who received ADA plus DMARDs than in those
who received DMARDs alone (P = 0.002 by log rank
test). Likewise, it was longer in those treated with ADA
alone than in those treated with DMARDs alone,
although this last difference was only of borderline statis-
tical significance (P = 0.051 by log rank test) (Figure 2B).
The time on treatment for ADA-based regimens
and DMARDs alone was independent of the presence of
organ manifestations other than vascular involvement (data
not shown). Among patients treated with ADA-based regi-
mens, there was no statistically significant difference in the
time on treatment between those having vascular involve-
ment as the sole disease manifestation (apart from oral
aphthosis) at the start of therapy and those having other
disease manifestations (P = 0.36 by log rank test) (Fig-
ure 2C). A comparable time on treatment was also
observed in DMARD-treated patients with or without
other disease manifestations (P = 0.83 by log rank test)
(Figure 2D).
During the follow-up period, 9 of 35 patients
(25.7%) discontinued ADA, due to lack of efficacy
(1 patient), loss of efficacy for vascular and extravascular
manifestations (3 patients each), and the occurrence of
generalized urticarial skin rash after ADA injection
(2 patients). With regard to the 3 subjects with vascular
relapse who had originally responded to ADA, 1 with an
initial stroke had a new stroke, 1 with initial bilateral SVT
had a recurrence of bilateral SVT, and 1 with initial bilat-
eral SVTand unilateral DVTexperienced a new unilateral
DVT. Among patients treated with DMARDs, 27 of 35
(77.1%) switched to other therapies, because of lack of
efficacy (6 patients), loss of efficacy (17 patients [14 for
vascular relapses]), adverse events (2 patients), and failure
of compliance (2 patients). Among the 14 patients with
vascular relapse after DMARD therapy, 5 with an initial
DVT had a new DVT, 2 with an initial SVTre-experienced
SVT, and 1 with an initial DVT developed an SVT; the
remaining 6 patients, who presented with both SVT and
DVTat diagnosis, had a new SVT (3 patients), a new DVT
(1 patient), or both an SVTand a DVT (2 patients).
The proportion of patients who discontinued ther-
apy because of loss of efficacy over time was significantly
higher among patients treated with DMARDs (P = 0.01).
Figure 3. Frequency of responsiveness to adalimumab (ADA)–based
regimens and disease-modifying antirheumatic drugs (DMARDs)
alone, with patients grouped according to the concomitant use of
anticoagulants. P values were obtained by Fisher’s exact test and com-
pare the frequency of efficacy (complete plus partial response) of
ADA-based regimens and DMARDs between patients who were
receiving anticoagulants and those who were not. Color figure can be
viewed in the online issue, which is available at http://onlinelibrary.
wiley.com/doi/10.1002/art.40531/abstract.
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The mean  SD time to vascular relapse was 29.9  24.4
months for patients treated with DMARDs and 33.7 
9.1 months for patients treated with ADA-based regimens.
We also assessed the effect of concomitant antico-
agulant therapy on vascular responses. Concomitant war-
farin therapy was given to 11 of 35 patients treated with
ADA-based regimens (7 of whom had DVTand 4 of whom
had both DVTand SVT) and to 10 of 35 patients treated
with DMARDs (1 of whom had recurrent SVT, 1 of whom
had DVT, and 8 of whom had both DVT and SVT) (P =
0.44). No differences were found in the frequency of
response to DMARDs (P = 0.26) or ADA-based regimens
(P = 0.31) between patients who were receiving anticoagu-
lants and those who were not (Figure 3). In addition, the
survival rates with ADA-based regimens or DMARDs
alone did not differ significantly between patients who
received anticoagulants and those who did not (P = 0.78
and P = 0.40, respectively) (Figure 4). In relation to the
safety profile, 1 case of herpes zoster virus reactivation and
1 case of pneumonia were recorded among patients trea-
ted with ADA-based regimens, along with the 2 aforemen-
tioned cases of generalized skin rash.
DISCUSSION
Vascular involvement in BS represents a clinical
issue in terms of morbidity and mortality (13), and opti-
mal clinical management still remains a matter of debate
(14,15). Anti-TNF agents are increasingly reported as
the treatment of choice for involvement of different
organs in BS (5,16–20); nevertheless, only few data are
available on the role of TNF inhibition in BS patients
with vascular involvement (10,21).
To the best of our knowledge, our study represents
the largest experience with the use of TNF blockers for
typical BS-related venous thrombosis. Indeed, although
venous thromboses (both DVTand recurrent SVT) are the
most frequent vascular manifestations in BS (13,22,23), the
role of TNF inhibitors has been mainly reported in patients
with arterial complications (10), especially those involving
pulmonary vessels (24–26). In contrast, infliximab has been
described as minimally effective in patients with atypical
venous involvement (Budd-Chiari syndrome) (21), while
its efficacy for DVTof the lower limbs has been only anec-
dotally reported (27).
Our retrospective evaluation shows that an ADA-
based regimen is a valuable choice for the treatment of
venous manifestations and that it achieves better results
than DMARDs alone. In particular, when DVT and/or
SVTwere present at the start of treatment, ADA-based reg-
imens induced vascular response in a significantly greater
proportion of patients than did DMARDs. Moreover,
ADA-based regimens induced a more rapid resolution of
the vascular manifestations as compared to DMARDs.
Consequently, as venous thrombosis requires early treat-
ment that can induce a quick response, TNF inhibition may
represent an optimal therapy in this clinical setting.
Anti-TNF agents have already been described as
having a corticosteroid-sparing effect in BS patients
(9,28), but specific data on patients with vascular manifes-
tations are lacking. In this regard, although in our study
no significant differences were found in the mean
Figure 4. Survival rates with adalimumab (ADA)–based regimens
(A) and regimens consisting of disease-modifying antirheumatic drugs
(DMARDs) alone (B), with patients grouped according to the con-
comitant use of anticoagulants. Color figure can be viewed in the
online issue, which is available at http://onlinelibrary.wiley.com/doi/10.
1002/art.40531/abstract.
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corticosteroid dosage between patients treated with ADA
and those administered DMARDs at the start of treat-
ments, steroid dosage was significantly lower among
patients treated with ADA at the last follow-up visit. As
also supported by the faster action of ADA-based regi-
mens, our data suggest that patients treated with ADA
are overall less exposed to systemic corticosteroids than
patients given DMARDs alone. This may allow a lower
rate of glucocorticoid-induced side effects in BS patients.
In our study, the proportion of patients discontinu-
ing treatment due to loss of efficacy over time was signifi-
cantly higher among those receiving DMARDs than
among those receiving ADA-based regimens. Moreover,
patients receiving ADA-based regimens (both as
monotherapy and combined with DMARDs) continued
treatment for a longer period of time than those given
DMARDs alone, with >50% of patients who received
ADA-based regimens continuing treatment after 80
months. Intriguingly, the time on treatment was signifi-
cantly longer for patients receiving combination therapy
(ADA plus DMARDs) than for those receiving DMARDs
alone. Similarly, patients receiving ADA monotherapy
tended to do so for a longer period of time than patients
receiving DMARDs alone. These data parallel those pre-
viously reported in other chronic inflammatory conditions,
such as rheumatoid arthritis (29). Of note, no differences
were found in time on treatment when the analysis was
stratified according to the presence or absence of manifes-
tations other than vascular involvement at the start of ther-
apies. This finding is of some interest to clinicians, since
apart from classic manifestations such as oral and genital
aphthous/ulcerative lesions, the clinical phenotypes of BS
are extremely diverse (30). Nevertheless, the therapeutic
outcome does not seem to be influenced by concurrent dis-
ease manifestations in patients with vascular involvement.
An interesting result of our study relates to the
role of oral anticoagulation for the treatment of BS-
related venous complications. This topic is one of the
most debated among BS specialists, and clear and definite
data on the real role of oral anticoagulation are lacking.
In particular, the EULAR recommendations do not sug-
gest the use of anticoagulants as first-line treatment, and
recent retrospective studies have shown that the risk of
DVT is lower in patients treated with immunosuppressive
agents than in those only receiving anticoagulants (31–
33). On the other hand, as recently pointed out by Seyahi
and Yazici (34), anticoagulation in BS patients might still
be of some help in nonendemic areas, where it is more
difficult for clinicians not familiar with BS to correctly
attribute vascular manifestations to BS itself.
In this context, anticoagulation in our patients
influenced neither the response rate nor the time on
treatment for ADA-based regimens and DMARD ther-
apy. Nevertheless, these results should be interpreted
with caution, as the lack of statistically significant differ-
ences in outcomes between patients with and those with-
out anticoagulation may be related to the limited size of
the study cohort. In the present study, adverse events
were rare in both groups, thus confirming the good safety
profile of ADA in the treatment of BS (35).
Our study has some limitations, mainly related to its
retrospective nature. In addition, in our study we only
included patients with “typical” venous events such as DVT
and SVT involving the upper and lower limbs. Indeed, the
response of some “atypical” venous events (e.g., suprahep-
atic thrombosis, vena cava thrombosis, or cerebral vein
thrombosis) is more difficult to objectively assess, thus
inducing us to exclude these kinds of vascular involvement,
while follow-up needed for arterial involvement is different
from that for venous involvement. However, some strengths
of our study warrant mention as well. This is the largest
study to investigate the efficacy of ADA-based regimens
compared to that of DMARDs alone for venous thrombo-
sis, and it is the only one to consider a homogeneous vascu-
lar involvement (DVT and/or SVT of lower and upper
limbs). These data shed some light on one of the major
complications of BS, indirectly confirming our previous
experimental data on the inflammatory nature of venous
thrombosis in this condition (3). Indeed, vascular involve-
ment in BS represents a unique example of inflammation-
induced thrombosis; experimental data (3), previous
clinical experience (4), and our own findings suggest the
use of immunosuppressants for vascular involvement in BS.
In conclusion, to date this is the largest study to
evaluate the role of TNF blockers in vascular BS and to
provide strong evidence in support of their use for the
treatment of venous thrombosis. In particular, we have
shown that ADA-based regimens are more effective and
rapid in inducing the resolution of venous involvement in
BS patients when compared to DMARDs used as
monotherapy. Their prompt effect allowed the minimiza-
tion of exposure to corticosteroids. Moreover, our findings
support the notion that anticoagulation does not modify
the efficacy of either ADA-based regimens or DMARDs,
thus strengthening the view that inflammation rather than
thrombophilic factors plays a role in the pathogenesis of
vascular complications in BS. Prospective controlled stud-
ies to corroborate our findings are warranted.
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